|
18 Jul 2023 |
Calidi Biotherapeutics and City of Hope Announce First Patient Dosed in a Phase 1 Clinical Trial Evaluating Neural Stem Cells Engineered to Carry an Oncolytic Virus, CLD-101, in Recurrent High-grade Glioma Patients
|
|
18 Jul 2023 |
Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate a Phase 1/2 Study of ARO-DUX4 for Facioscapulohumeral Muscular Dystrophy
|
|
17 Jul 2023 |
Alnylam Reports Updated Positive Interim Phase 1 Results for ALN-APP, in Development for Alzheimer’s Disease and Cerebral Amyloid Angiopathy
|
|
17 Jul 2023 |
RNA-Targeted Novel Drug Modalities Based on RNA Editing, Epitranscriptomics, Direct RNA Targeting, Splicing Modulation, Translation Regulation, lncRNA & regRNA Targeting & More
|
|
15 Jul 2023 |
Caribou Biosciences Reports Positive Clinical Data from Dose Escalation of CB-010 ANTLER Phase 1 Trial in r/r B-NHL
|
|
13 Jul 2023 |
Invectys Announces Initiation of Phase 1/2a Clinical Trial in Solid Tumors and Change in Leadership
|
|
13 Jul 2023 |
EG 427 announces final Series A closing, achieving €18 million in total funds raised
|
|
11 Jul 2023 |
IconOVir Bio Announces First Patient Dosed in Phase 1 Clinical Trial of its Lead Product Candidate, ICVB-1042
|
|
11 Jul 2023 |
Phase 1 Study Indicates Allogeneic Cytokine-Induced Memory-Like Natural Killer Cells Plus N-803 May Induce Tumor Regression in Advanced Head-and-Neck Cancer Patients
|
|
11 Jul 2023 |
Elsie Biotechnologies Announces Collaboration with GSK to Accelerate Oligonucleotide Discovery Technologies
|
|
10 Jul 2023 |
Sensorion Submits Clinical Trial Application for Lead Gene Therapy Candidate OTOF-GT in the UK
|
|
06 Jul 2023 |
Hillstream BioPharma Licenses Technology to Develop Proprietary HER2 and HER3 Antibody Drug Conjugates against Drug-Resistant Breast, Lung, Gastric, and Ovarian Cancers
|
|
06 Jul 2023 |
Kyverna Therapeutics Announces Regulatory Approval of Phase 1/2 Clinical Trial for KYV-101 in Germany
|
|
06 Jul 2023 |
Altamira Therapeutics Announces Collaboration with Heqet Therapeutics on Nanoparticle-Delivered Non-Coding RNAs for Cardiac Regeneration
|
|
06 Jul 2023 |
Poseida Therapeutics Announces FDA Clearance of Investigational New Drug Application for P-CD19CD20-ALLO1, an Allogeneic Dual CAR-T Cell Therapy for B-Cell Malignancies
|
|
03 Jul 2023 |
Krystal Biotech Announces First Patient Dosed in Phase 1 Clinical Trial of KB407 for the Treatment of Cystic Fibrosis
|
|
03 Jul 2023 |
Skyline Therapeutics Receives FDA Clearance of IND for SKG0106, a Novel Intravitreally Delivered AAV Gene Therapy Candidate for Neovascular Age-related Macular Degeneration
|
|
03 Jul 2023 |
IASO Bio and Innovent Announce the NMPA Approval of the New Drug Application for Equecabtagene Autoleucel, the World's First Fully-human BCMA CAR-T Therapy, for the Treatment of Relapsed and/or Refractory Multiple Myeloma
|
|
30 Jun 2023 |
Kyverna Therapeutics Announces First Patient Enrolled in Phase 1 Clinical Trial of CD19 CAR T-cell Therapy for Lupus Nephritis in the U.S.
|
|
30 Jun 2023 |
U.S. Food and Drug Administration Approves BioMarin's ROCTAVIAN™ (valoctocogene roxaparvovec-rvox), the First and Only Gene Therapy for Adults with Severe Hemophilia A
|
|
29 Jun 2023 |
Carisma Therapeutics Announces First Patient Dosed in Phase 1 Study of CT-0508 in Combination with KEYTRUDA® (pembrolizumab) in Patients with HER2 Overexpressing Solid Tumors
|
|
29 Jun 2023 |
FDA Approves First Cellular Therapy to Treat Patients with Type 1 Diabetes
|
|
28 Jun 2023 |
FDA Accepts Pfizer’s Application for Hemophilia B Gene Therapy Fidanacogene Elaparvovec
|
|
28 Jun 2023 |
BlueRock’s neuronal stem cell therapy for Parkinson’s disease is first to show positive results in Phase I clinical study
|
|
28 Jun 2023 |
MeiraGTx Announces Positive Clinical Data from the AQUAx Phase 1 Clinical Study of AAV2-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia
|
